Dimension Vista System B2 Microglobulin Flex reagent cartridge and urine stabilizer Catalo...
FDA Device Recall #Z-1030-2016 — Class II — November 3, 2015
Recall Summary
| Recall Number | Z-1030-2016 |
| Classification | Class II — Moderate risk |
| Date Initiated | November 3, 2015 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Siemens Healthcare Diagnostics, Inc. |
| Location | Newark, DE |
| Product Type | Devices |
| Quantity | 1637 units. |
Product Description
Dimension Vista System B2 Microglobulin Flex reagent cartridge and urine stabilizer Catalog #K7024 SMN: 10445889 Lot #15246MA Product Usage: The B2MIC method is an in vitro diagnostic test for the quantitative measurement of B2-microglobulin in human serum, heparinized plasma, EDTA plasma and urine on the Dimension Vista System. Measurements of B2-microglobulin aid in the diagnosis of active rheumatoid arthritis and kidney disease.
Reason for Recall
Siemens Healthcare Diagnostics has confirmed an increase in the rate of Abnormal Assay errors and calibration failures with the Dimension Vista B2MIC Flex reagent cartridge: Dimension Vista System Flex reagent cartridge and urine stabilizer B2MIC. In the unlikely event that a patient result is generated, a suppressed result would be in conflict with the patients clinical status and other markers of renal injury.
Distribution Pattern
Worldwide Distribution and US in the state of CA.
Lot / Code Information
Lot #: 15037MA - foreign 15175MA - foreign 15204MA- foreign 15246MA (Distributed in US) 15267MA - foreign
Other Recalls from Siemens Healthcare Diagnostics, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-1484-2026 | Class II | Atellica CH Urine Albumin (UAlb). Material Numb... | Jan 20, 2026 |
| Z-0491-2026 | Class II | IMMULITE 2000 Oak Mix Specific Allergen; Sieme... | Oct 6, 2025 |
| Z-0492-2026 | Class II | 3gAllergy Specific IgE Universal Kit; Kit Comp... | Oct 6, 2025 |
| Z-0493-2026 | Class II | Food Panel 3 Specific Allergen; Siemens Materi... | Oct 6, 2025 |
| Z-0366-2026 | Class II | Assay: IMMULITE 2000 Intact PTH; Test Code: iP... | Sep 22, 2025 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.